title: New AHA and ACC guidelines on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk.
abstract: After the publication of the new guidelines of the European Society of Cardiology and the European Atherosclerosis Society for the prevention and treatment of dyslipidemias (Eur Heart J 32:1769-1818, 2011; Eur Heart J 33:1635-1701, 2012), a group of authors has recently published on behalf of the American Heart Association and the American College of Cardiology guidelines on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk (Circulation 2013). These new guidelines are supposed to replace the until now widely accepted, at least in the USA, recommendations of the National Cholesterol Education Program Adult Treatment Panel III from the years 2002 (Circulation 106:3143-3421, 2002) and 2004 (Circulation 110:227-39, 2004). Furthermore, they claim to be based mainly on hard evidence derived from the interpretation of results of prospective randomized controlled trials. This Joint Position Statement of the Society for the Prevention of Cardiovascular Diseases e.V. (D.A.CH), the Austrian Atherosclerosis Society and the Working Group on Lipids and Atherosclerosis (AGLA) of the Swiss Society of Cardiology concludes that the use of individualized prevention strategies based on specific indications and LDL cholesterol target concentrations, a strategy whose worth has been widely proven and accepted for more than a decade in Europe, should not be given up.
authors.affiliation: Practice for Internal Medicine, Gastroenterology, Cardiology and Preventive Medicine, Bremen, Germany.
authors.forename: Gerald
authors.initials: G
authors.lastname: Klose
authors.forename: Frank Ulrich
authors.initials: FU
authors.lastname: Beil
authors.forename: Hans
authors.initials: H
authors.lastname: Dieplinger
authors.forename: Arnold
authors.initials: A
authors.lastname: von Eckardstein
authors.forename: Bernhard
authors.initials: B
authors.lastname: Föger
authors.forename: Ioanna
authors.initials: I
authors.lastname: Gouni-Berthold
authors.forename: Franz
authors.initials: F
authors.lastname: Heigl
authors.forename: Wolfgang
authors.initials: W
authors.lastname: Koenig
authors.forename: Gert M
authors.initials: GM
authors.lastname: Kostner
authors.forename: Ulf
authors.initials: U
authors.lastname: Landmesser
authors.forename: Ulrich
authors.initials: U
authors.lastname: Laufs
authors.forename: Frank
authors.initials: F
authors.lastname: Leistikow
authors.forename: Winfried
authors.initials: W
authors.lastname: März
authors.forename: Georg
authors.initials: G
authors.lastname: Noll
authors.forename: Klaus G
authors.initials: KG
authors.lastname: Parhofer
authors.forename: Bernhard
authors.initials: B
authors.lastname: Paulweber
authors.forename: Walter F
authors.initials: WF
authors.lastname: Riesen
authors.forename: Jürgen R
authors.initials: JR
authors.lastname: Schaefer
authors.forename: Elisabeth
authors.initials: E
authors.lastname: Steinhagen-Thiessen
authors.forename: Armin
authors.initials: A
authors.lastname: Steinmetz
authors.forename: Hermann
authors.initials: H
authors.lastname: Toplak
authors.forename: Christoph
authors.initials: C
authors.lastname: Wanner
authors.forename: Eberhard
authors.initials: E
authors.lastname: Windler
mesh_terms: D000328:Adult; D000368:Aged; D050197:Atherosclerosis / Q000097:blood / Q000401:mortality / Q000628:therapy*; D002423:Cause of Death; D008078:Cholesterol, LDL / Q000097:blood; D003131:Combined Modality Therapy; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000401:mortality / Q000628:therapy; D005060:Europe; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D006937:Hypercholesterolemia / Q000097:blood / Q000401:mortality / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D040242:Risk Reduction Behavior; D015996:Survival Rate
chemical_list: D008078:Cholesterol, LDL; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors